AUTX-703
A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 69 patients (estimated)
- Sponsors
- Auron Therapeutics, Inc.
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 2088
- NCT Identifier
- NCT06846606
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.